Vascular smooth muscle cell proliferation in restenosis

Circulation: Cardiovascular Interventions

Volumn 4, Issue 1, 2011, Pages 104-111

  Marx, Steven O ^a,b   Totary Jain, Hana ^b   Marks, Andrew R ^b  

^a Clyde and Helen Wu Center for Molecular Cardiology   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; INTERLEUKIN 1; INTERLEUKIN 6; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 21; MICRORNA 221; MICRORNA 222; NITRIC OXIDE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; IN-STENT RESTENOSIS; NEOINTIMA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CELL PROLIFERATION; CORONARY RESTENOSIS; HUMANS; MUSCLE, SMOOTH, VASCULAR; STENTS; TREATMENT OUTCOME;

EID: 79954441802     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.957332     Document Type: Article

References (100)

1. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333. (Pubitemid 13012062)
2. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208 -215. (Pubitemid 13039947)
3. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77B-88B.
4. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998; 98:82- 89. (Pubitemid 28312083)
5. Kim MS, Dean LS. In-Stent Restenosis. Cardiovasc Ther. April 9, 2010. [Epub ahead of print.].
6. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758 -769.
7. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769 -1776. (Pubitemid 35315761)
8. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257-2273. (Pubitemid 40632443)
9. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res. 1986;58:427- 444. (Pubitemid 16102201)
10. Orlandi A, Bennett M. Progenitor cell-derived smooth muscle cells in vascular disease. Biochem Pharmacol. 2010;79:1706 -1713.
11. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996;94:1655-1664. (Pubitemid 26320272)
12. Wilcox JN, Cipolla GD, Martin FH, Simonet L, Dunn B, Ross CE, Scott NA. Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Ann N Y Acad Sci. 1997;811:437- 447. (Pubitemid 27308351)
13. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Simonet L, Wilcox JN. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 1996;93:2178 -2187. (Pubitemid 26187108)
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801- 809. (Pubitemid 23132154)
15. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403- 409. (Pubitemid 34407037)
16. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, Litzow MR, Edwards WD. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003;100: 4754-4759. (Pubitemid 36457802)
17. Pardee AB. G1 events and regulation of cell proliferation. Science. 1989;246:603- 608.
18. Sherr CJ. The ins and outs of RB: coupling gene expression to the cell cycle clock. Trends Cell Biol. 1994;4:15-18. (Pubitemid 24038742)
19. Sherr CJ. Growth factor-regulated G1 cyclins. Stem Cells. 1994; 12(Suppl 1):47-55.
20. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996;274:1664 -1672. (Pubitemid 26414889)
21. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/Sregulatory genes. Mol Cell Biol. 1995;15:4215- 4224.
22. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149 -1163.
23. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000;101:2022-2025. (Pubitemid 30233162)
24. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994; 8:9 -22.
25. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirusmediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260 -2268.
26. Boehm M, Olive M, True AL, Crook MF, San H, Qu X, Nabel EG. Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism. J Clin Invest. 2004;114:419-426. (Pubitemid 39071614)
27. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res. 2007;100:607- 621. (Pubitemid 46594875)
28. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006;290: C661-C668.
29. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factordirected migration by vascular smooth muscle cells. Hypertension. 1997; 29:334-339. (Pubitemid 27074065)
30. Scherberich A, Campos-Toimil M, Ronde P, Takeda K, Beretz A. Migration of human vascular smooth muscle cells involves serumdependent repeated cytosolic calcium transients. J Cell Sci. 2000;113(Pt 4):653- 662. (Pubitemid 30133043)
31. Fukui R, Amakawa M, Hoshiga M, Shibata N, Kohbayashi E, Seto M, Sasaki Y, Ueno T, Negoro N, Nakakoji T, Ii M, Nishiguchi F, Ishihara T, Ohsawa N. Increased migration in late G(1) phase in cultured smooth muscle cells. Am J Physiol Cell Physiol. 2000;279:C999-C1007.
32. Goukassian D, Diez-Juan A, Asahara T, Schratzberger P, Silver M, Murayama T, Isner JM, Andres V. Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J. 2001;15: 1877-1885. (Pubitemid 32848791)
33. Fukui R, Shibata N, Kohbayashi E, Amakawa M, Furutama D, Hoshiga M, Negoro N, Nakakouji T, Ii M, Ishihara T, Ohsawa N. Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis. 1997;132:53-59. (Pubitemid 27306739)
34. Diez-Juan A, Andres V. Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res. 2003;92:402- 410. (Pubitemid 36298200)
35. Parmacek MS. MicroRNA-modulated targeting of vascular smooth muscle cells. J Clin Invest. 2009;119:2526 -2528.
36. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20. (Pubitemid 40094598)
37. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
38. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNAmediated gene silencing. Cell. 2008;132:9 -14.
39. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304:594 -596. (Pubitemid 38541919)
40. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
41. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460: 705-710.
42. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158 -166.
43. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, Hein L, Braun T. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119:2634 -2647.
44. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009;16:1590 -1598.
45. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009;104:476-487.
46. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009; 284:3728 -3738.
47. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579 -1588. (Pubitemid 46897261)
48. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, Richardson JA, Bassel-Duby R, Olson EN. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166 -2178.
49. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272-284.
50. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 2008;105:1516 -1521. (Pubitemid 351346546)
51. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic, II: fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28:727-732.
52. Sehgal SN, Bansbach CC. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann N Y Acad Sci. 1993;685:58-67. (Pubitemid 23238476)
53. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756 -758.
54. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A. 1994;91:12574 -12578.
55. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycindependent fashion and is homologous to yeast TORs. Cell. 1994;78: 35-43. (Pubitemid 24228298)
56. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12- rapamycin complex in mammalian cells. J Biol Chem. 1995;270: 815-822.
57. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729 -734. (Pubitemid 44286004)
58. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159 -168.
59. Kohn AD, Kovacina KS, Roth RA. Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. EMBO J. 1995;14:4288-4295.
60. Thomas G. The S6 kinase signaling pathway in the control of development and growth. Biol Res. 2002;35:305-313. (Pubitemid 35189803)
61. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807- 826. (Pubitemid 32295062)
62. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570 -573.
63. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol. 1996;16:6744-6751. (Pubitemid 26389733)
64. Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood. 1998;91:561-569. (Pubitemid 28053379)
65. Morris RE, Cao W, Huang X, Gregory CR, Billingham ME, Rowan R, Shorthouse RA. Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc. 1995;27:430-431.
66. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation. 1993;55:1409 -1418. (Pubitemid 23183261)
67. Jayaraman T, Marks AR. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J Biol Chem. 1993;268:25385-25388. (Pubitemid 23358140)
68. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412- 417.
69. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283. (Pubitemid 26394201)
70. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation. 2001; 103:2967-2972. (Pubitemid 32578136)
71. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852- 855. (Pubitemid 32778031)
72. Moss SC, Lightell DJ Jr, Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclindependent kinase inhibitor p27Kip1. J Biol Chem. 2010;285:11991-11997.
73. Roque M, Reis ED, Cordon-Cardo C, Taubman MB, Fallon JT, Fuster V, Badimon JJ. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab Invest. 2001;81:895-903. (Pubitemid 32553410)
74. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164- 2170. (Pubitemid 29196802)
75. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188 -1193. (Pubitemid 32830406)
76. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346: 1773-1780. (Pubitemid 34586912)
77. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195. (Pubitemid 32095401)
78. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. (Pubitemid 37186209)
79. Ruygrok PN, Desaga M, Van Den Branden F, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys PW. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention. 2007;3:315-320.
80. Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJ. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). J Am Coll Cardiol Cardiovasc Interv. 2009;2:1208-1218.
81. Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, Trubelja N, Carlier SG, Mehran R, Dangas GD, Weisz G, Kreps EM, Collins M, Stone GW, Moses JW. A prospective registry to evaluate sirolimuseluting stents implanted at coronary bifurcation lesions using the "crush technique." Am J Cardiol. 2006;97:1317-1321.
82. Scheen AJ, Warzee F, Legrand VM. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J. 2004;25:2167-2169.
83. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R, Somers VK. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol. 2007;100:234 -239.
84. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104:3052-3056. (Pubitemid 34014056)
85. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44:1819 -1824. (Pubitemid 39424081)
86. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189: 47-60. (Pubitemid 44441296)
87. Shan J, Nguyen TB, Totary-Jain H, Dansky H, Marx SO, Marks AR. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci U S A. 2008;105:19006 -19011.
88. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol. 1999;178:235-246. (Pubitemid 29034867)
89. Vinals F, Chambard JC, Pouyssegur J. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem. 1999;274:26776 -26782.
90. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents, VI: the isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325-2327.
91. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, Heinle H, Karsch KR. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969 -1976. (Pubitemid 30342882)
92. Arnal I, Wade RH. How does taxol stabilize microtubules? Curr Biol. 1995;5:900 -908.
93. Caplow M, Shanks J, Ruhlen R. How taxol modulates microtubule disassembly. J Biol Chem. 1994;269:23399 -23402. (Pubitemid 24293533)
94. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995; 332:1004 -1014.
95. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, Froehlich JP, Crow MT, Lakatta EG, Rowinsky EK. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869 -1876.
96. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645. (Pubitemid 27329445)
97. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42. (Pubitemid 36070930)
98. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME. Randomized study to assess the effectiveness of slow- and moderaterelease polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788 -794. (Pubitemid 37022118)
99. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-1947. (Pubitemid 38544483)
100. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231. (Pubitemid 38067635)